Ledipasvir
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09027 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 30 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hepatitis B virus infection | KG + DL |
| 2 | hepatitis E virus infection | KG + DL |
| 3 | hepatitis, viral, animal | KG + DL |
| 4 | hepatitis A virus infection | KG + DL |
| 5 | Omsk hemorrhagic fever | KG + DL |
| 6 | Kyasanur forest disease | KG + DL |
| 7 | chronic hepatitis B virus infection | KG + DL |
| 8 | HIV infectious disease | KG + DL |
| 9 | simian immunodeficiency virus infection | KG + DL |
| 10 | feline acquired immunodeficiency syndrome | KG + DL |
| 11 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | KG + DL |
| 12 | obsolete familial combined hyperlipidemia | KG + DL |
| 13 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 14 | primitive portal vein thrombosis | KG + DL |
| 15 | hepatoportal sclerosis | KG + DL |
| 16 | idiopathic copper-associated cirrhosis | KG + DL |
| 17 | hepatopulmonary syndrome | KG + DL |
| 18 | hepatic porphyria | KG + DL |
| 19 | fibroma of prostate | KG + DL |
| 20 | Brenner tumor | KG + DL |
| 21 | benign reproductive system neoplasm | KG + DL |
| 22 | benign prostate phyllodes tumor | KG + DL |
| 23 | male reproductive organ cancer | KG + DL |
| 24 | prostate leiomyoma | KG + DL |
| 25 | prostate cancer/brain cancer susceptibility | KG + DL |
| 26 | Ledderhose disease | KG + DL |
| 27 | palmar fibromatosis | KG + DL |
| 28 | infantile digital fibromatosis | KG + DL |
| 29 | penile fibromatosis | KG + DL |
| 30 | hypercholesterolemia, autosomal dominant | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.